Last reviewed · How we verify
Basiliximab 20 milligram [Simulect]
Basiliximab 20 milligram [Simulect] is a Small molecule drug developed by King Faisal Specialist Hospital & Research Center. It is currently FDA-approved.
Basiliximab 20 milligram [Simulect] is a marketed drug developed by King Faisal Specialist Hospital & Research Center, with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and patent protection, which helps maintain its competitive edge. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | Basiliximab 20 milligram [Simulect] |
|---|---|
| Sponsor | King Faisal Specialist Hospital & Research Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Basiliximab 20 milligram [Simulect] CI brief — competitive landscape report
- Basiliximab 20 milligram [Simulect] updates RSS · CI watch RSS
- King Faisal Specialist Hospital & Research Center portfolio CI
Frequently asked questions about Basiliximab 20 milligram [Simulect]
What is Basiliximab 20 milligram [Simulect]?
Who makes Basiliximab 20 milligram [Simulect]?
What development phase is Basiliximab 20 milligram [Simulect] in?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing